Starting with the unexpected differences in predicted CD4 downmodulation between RA patients and healthy subjects, we were able to demonstrate that the disulphide bridge in D2 of the CD4 molecule, which can be selectively reduced by Trx1,13 is important for the Tregalizumab–CD4 interaction. This evidence concerns the gene TXN and rheumatoid arthritis.